Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Gurnari C, Prata PH, Catto LFB, Durmaz A, Larcher L, Sebert M, Allain V, Kewan T, Pagliuca S, Pinto AL, Inacio MCB, Hernandez L, Dhedin N, Caillat-Zucman S, Clappier E, Sicre de Fontbrune F, Voso MT, Visconte V, Peffault de Latour R, Soulier J, Socié G, Calado RT, Maciejewski JP. Gurnari C, et al. Among authors: sebert m. Blood. 2023 Jun 22;141(25):3122-3125. doi: 10.1182/blood.2023020108. Blood. 2023. PMID: 37053552 No abstract available.
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G. Lainey E, et al. Among authors: sebert m. Cell Cycle. 2012 Nov 1;11(21):4079-92. doi: 10.4161/cc.22382. Epub 2012 Oct 24. Cell Cycle. 2012. PMID: 23095522 Free PMC article.
Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.
Tailler M, Senovilla L, Lainey E, Thépot S, Métivier D, Sébert M, Baud V, Billot K, Fenaux P, Galluzzi L, Boehrer S, Kroemer G, Kepp O. Tailler M, et al. Among authors: sebert m. Oncogene. 2012 Jul 26;31(30):3536-46. doi: 10.1038/onc.2011.521. Epub 2011 Nov 21. Oncogene. 2012. PMID: 22105358
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L. Le Bras F, et al. Among authors: sebert m. Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28. Leuk Res. 2011. PMID: 21715006
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases.
Zakine È, Papageorgiou L, Bourguiba R, Mekinian A, Terrier B, Kosmider O, Hirsch P, Jachiet M, Audia S, Ardois S, Adélaïde L, Bigot A, Duriez P, Emile JF, Lazaro E, Fayard D, Galland J, Hié M, Humbert S, Jean A, Kostine M, Lacombe V, Le Guenno G, Lobbes H, Magy-Bertrand N, Marianetti-Guingel P, Mathian A, Outh R, Saillard C, Samson M, Vial G, Bouaziz JD, Moguelet P, Chasset F; National French VEXAS Study Group (NFVS). Zakine È, et al. J Am Acad Dermatol. 2023 Apr;88(4):917-920. doi: 10.1016/j.jaad.2022.10.052. Epub 2022 Nov 5. J Am Acad Dermatol. 2023. PMID: 36343774 No abstract available.
USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.
Delplanque M, Aouba A, Hirsch P, Fenaux P, Graveleau J, Malard F, Roos-Weil D, Belfeki N, Drevon L, Oganesyan A, Groh M, Mahévas M, Razanamahery J, Maigne G, Décamp M, Miranda S, Quemeneur T, Rossignol J, Sailler L, Sébert M, Terriou L, Sevoyan A, Hakobyan Y, Georgin-Lavialle S, Mekinian A. Delplanque M, et al. Among authors: sebert m. J Clin Med. 2021 Nov 27;10(23):5586. doi: 10.3390/jcm10235586. J Clin Med. 2021. PMID: 34884286 Free PMC article.
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S. Thépot S, et al. Among authors: sebert m. Cell Cycle. 2011 Jul 15;10(14):2323-30. doi: 10.4161/cc.10.14.16399. Epub 2011 Jul 15. Cell Cycle. 2011. PMID: 21654193
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM). Sébert M, et al. Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7. Haematologica. 2019. PMID: 30733271 Free PMC article. Clinical Trial.
101 results